Clinical Trial

A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate safety and tolerability, pharmacokinetics （PK）, efficacy of TRC003 injection in patients with progressive PSMA-positive mCRPC who have been treated with androgen receptor pathway inhibitor (ARPI) or taxane-based chemotherapy. We plan to recruit 90 participants who will be randomly assigned to 1 of 3 dose cohorts (30 cases per dose cohort) with up to 6 cycles of treatment in this study.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-30
Trial Details
NCT Number NCT07567521
Lead Sponsor C Ray Therapeutics
Conditions Prostate Cancer
Enrollment 90 participants
Start Date 2026-05-22
Primary Completion 2027-12-30 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-29